[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"delayed-sleep-phase-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:delayed-sleep-phase-syndrome":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100552306","pathophysiology-of-circadian-rhythm-delayed-sleep-wake-phase-disorder-100552306",false,"NCT06471374","Pathophysiology of Circadian Rhythm Delayed Sleep Wake Phase Disorder","Inclusion Criteria:\n\n* Delayed sleep wake phase disorder diagnosis\n* Altitude history: currently residing at Denver altitude or higher\n* BMI normal to moderately overweight\n\nExclusion Criteria:\n\n* Recent medical condition\n* Psychiatric disorder\n* Sleep disorder\n* Medication use",true,"ALL","16 Years","40 Years",{"count":20,"type":21},66,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this study is to understand factors that contribute to delayed sleep wake phase disorder (DSWPD). The investigators will examine whether patients with DSWPD exhibit alterations in circadian rhythms and sensitivity to light compared to healthy controls. The investigators will also test a new method of predicting circadian rhythms form a blood sample.",[27,28],"Delayed Sleep Phase Syndrome","Delayed Sleep Phase","RECRUITING","2026-06-15",{"date":32,"type":33},"2026-06-17","ACTUAL",{"date":35,"type":33},"2024-04-02",{"date":37,"type":21},"2028-07",{"name":39,"class":40},"University of Colorado, Boulder","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":15,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":66},"100583325","phase-4-lemborexant-in-delayed-sleep-phase-syndrome-100583325","NCT06874855","Lemborexant in Delayed Sleep Phase Syndrome","Inclusion Criteria:\n\n\\- Participants will be required to be 18 years of age or older and have delayed sleep phase syndrome (DSPS). Questionnaires will be used to identify potential confounders and to confirm a potential diagnosis of DSPS based on ICSD3 criteria: a) Sleep is delayed by two hours or more beyond what is considered an acceptable or conventional bedtime for the subject (their desired bedtime). b) Subjects not able to fall asleep if trying to sleep before the later bedtime; c) This is interfering with their wishes\u002Fhaving a social impact. Concomitant medications will be allowed, though dosages will be required to remain fixed throughout participation in the study. The participant also needs to be willing and able to comply with all aspects of the protocol.\n\nExclusion Criteria:\n\n* Clinically significant depression (PHQ-9 score of 10 or more), anxiety disorder (GAD- 7 score of 10 or more), substance use disorder, any other sleep disorder, or any medical disorder\u002Ftherapy that could interfere with the trial\n* Use of medications with significant effects on sleep-wake function (insomnia therapies, stimulants)- unless they are discontinued at least 5 half-lives prior to study participation. Non-sedative antidepressants or SSRI will be allowed if at a stable dose in the absence of concomitant severe depression or severe anxiety.\n* Use of CYP3A inhibitors and CYP3A inducers, at least 1 week (or five half-lives, whichever is longer) prior to the first day of the baseline phase.\n* Pregnancy (verified by urine pregnancy test on visits 1, 2, and 3) or plan to become pregnant in the next 3 months or currently breastfeeding.\n* Shift workers or subjects working unusual hours.\n* Transmeridian travel across more than 3 time zones 4 weeks prior to the screening phase.\n* Transmeridian travel across more than 2 time zones during this trial (including the screening phase).\n* Having a positive drug test or being unwilling to refrain from using illegal drugs or marijuana during this trial.\n* Any clinically abnormal symptom or organ impairment found by medical history at Screening or Baseline and physical examinations, vital signs, or laboratory test results that require medical treatment.\n* Impaired liver function (values for enzymes aspartate transaminase (AST) and alanine transaminase (ALT) \\> 1.5 times the Upper Limit of Normal).\n* Known to be human immunodeficiency virus positive.","18 Years",{"count":49,"type":21},15,[51],"PHASE4","The purpose of the study is to evaluate whether Lemborexant is more effective than placebo in shortening sleep onset latency in patients with delayed sleep phase syndrome (both type 1 and type 2). This will be tracked using sleep logs as well as actigraphy.\n\nIn this 2-year study, the investigators will examine if Lemborexant administered 5-10 mg nightly taken at desired bedtime (at least 2 hours prior to self-reported sleep onset habitual time) can improve the symptoms of Delayed Sleep Phase Syndrome.",[27],[27,55,56],"Syndrome","Lemborexant","2026-06-03",{"date":59,"type":33},"2026-06-05",{"date":61,"type":33},"2023-03-13",{"date":63,"type":21},"2027-05-31",{"name":65,"class":40},"University of California, San Francisco",1]